COMPANY

Autobahn Therapeutics

HQ: San Diego, CA source · autobahntx.com ↗ · West Coast

Our lead molecule, elunetirom (ABX-002), is a potent and selective, CNS-directed thyroid receptor (CNS-TR) agonist that we are developing as a potential treatment for multiple CNS disorders, initially focusing on the adjunctive treatment for people with major depressive disorder (MDD) and bipolar disorder depression. From company website Source · Oct 12, 2026

Keywords: ABX-002 Bipolar Disorder Depression MDD

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Raises and deals from press releases

Raise Series C · $100M · announced Jul 24, 2024 Company release ↗
Source quote
- Jul 24, 2024 · Company release ↗
  “– Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the closing of an oversubscribed $100 million Series C financing led by Newpath Partners”

Raises announced in these releases: $100M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Mar 28, 2025 Trial start Phase 2: Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults source ↗
Jan 2, 2025 Trial start Phase 1: ABX-002 Bioequivalence and Effect of Food Study in Healthy Adult Participants source ↗
Sep 20, 2024 Trial start Phase 2: Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) source ↗
Jul 24, 2024 Raise Series C · $100M source ↗
Oct 12, 2022 Trial start Phase 1: SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT07652697	ABX-002 Bioequivalence and Effect of Food Study in Healthy Adult Participants	Phase 1	Completed	Jan 2, 2025	Feb 17, 2025 (actual)
NCT06869187	Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults	Phase 2	Active, not recruiting	Mar 28, 2025	Apr 22, 2026 (actual)
NCT06633016	Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)	Phase 2	Recruiting	Sep 20, 2024	2026-06 (estimated)
NCT05528315	SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects	Phase 1	Completed	Oct 12, 2022	Jun 26, 2023 (actual)

Connect

Contact page